Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 9/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.40 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.40 |
| ▸ | PIM1 | P11309 | 2/20 | 0.40 |
| ▸ | GSK3A | P49840 | 2/20 | 0.40 |
| ▸ | GSK3B | P49841 | 2/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.40 |
| ▸ | PIM3 | Q86V86 | 2/20 | 0.40 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.40 |
| ▸ | CDC7 | O00311 | 1/20 | 0.40 |
| ▸ | IKBKB | O14920 | 1/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.40 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.40 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1276252 | 0.68 | PDPK1 (0.32) | PDPK1PARP1DAPK3PRKD3PIM1 | |
| SCHEMBL8664696 | 0.68 | LIMK1 (0.39) | DAPK3PRKD3PIM1GSK3AGSK3B | |
| Hypoxanthine SCHEMBL822613 | 0.63 | TSHR (0.47) | PDPK1PARP1ACHEGDARAB9A | |
| SCHEMBL16256173 | 0.62 | PDPK1 (0.63) | PDPK1PARP1RAB9ASMN1; SMN2DAPK3 | |
| SCHEMBL16384769 | 0.62 | ALDH1A1 (0.45) | PDPK1PARP1RAB9ASMN1; SMN2DAPK3 | |
| SCHEMBL10565996 | 0.62 | PDPK1 (0.58) | PDPK1PARP1RAB9ASMN1; SMN2DAPK3 | |
| SCHEMBL4212348 | 0.62 | NPC1 (0.60) | PDPK1PARP1RAB9ASMN1; SMN2DAPK3 | |
| SCHEMBL16384767 | 0.62 | PDPK1 (0.58) | PDPK1PARP1RAB9ASMN1; SMN2DAPK3 | |
| SCHEMBL10565373 | 0.62 | PIM1 (0.57) | PDPK1PARP1DAPK3PRKD3PIM1 | |
| SCHEMBL3357774 | 0.61 | ALDH1A1 (0.50) | PDPK1PARP1RAB9ASMN1; SMN2DAPK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114846140-A | Pharmaceutical combination of a therapeutic oligonucleotide targeting HBV and a TLR7 agonist for the treatment of HBV | 豪夫迈·罗氏有限公司 | 2022-08-02 | — | — | CN | claimed |
| US-20180000824-A1 | COMBINED TREATMENT WITH A TLR7 AGONIST AND AN HBV CAPSID ASSEMBLY INHIBITOR | HOFFMANN-LA ROCHE INC. (US) | 2018-01-04 | — | — | US | claimed |
| CN-117321070-A | Virus targeting to hematopoietic stem cells | 麻省理工学院 | 2023-12-29 | — | — | CN | disclosed |
| CN-114846140-A | Pharmaceutical combination of a therapeutic oligonucleotide targeting HBV and a TLR7 agonist for the treatment of HBV | 豪夫迈·罗氏有限公司 | 2022-08-02 | — | — | CN | disclosed |
| CN-114828852-A | HBV-targeted antiviral and/or immunomodulatory agent pharmaceutical combinations for the treatment of HBV | 豪夫迈·罗氏有限公司 | 2022-07-29 | — | — | CN | disclosed |
| EP-4001283-A1 | SUBSTITUTED AMINOTHIAZOLOPYRIMIDINEDIONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF VIRUS INFECTION | F. Hoffmann-La Roche AG (CH) | 2022-05-25 | — | — | EP | disclosed |
| CN-113813386-A | Combination tumor immunotherapy | 查克美特制药公司 | 2021-12-21 | — | — | CN | disclosed |
| CN-107746852-B | Prostate-associated antigens and vaccine-based immunotherapeutic therapies | 辉瑞公司 | 2021-10-08 | — | — | CN | disclosed |
| CN-107428813-B | Combination tumor immunotherapy | 查克美特制药公司 | 2021-08-03 | — | — | CN | disclosed |
| CN-107427514-B | Combination therapy using a TLR7 agonist and an HBV capsid assembly inhibitor | 豪夫迈·罗氏有限公司 | 2021-07-13 | — | — | CN | disclosed |
| CN-110753756-A | Immunomodulatory polynucleotides and uses thereof | 长春华普生物技术股份有限公司 | 2020-02-04 | — | — | CN | disclosed |
| WO-2017211791-A1 | COMBINATION THERAPY OF AN HBSAG INHIBITOR AND A TLR7 AGONIST | F. HOFFMANN-LA ROCHE AG (CH) | 2017-12-14 | — | — | WO | disclosed |
| EP-2561872-B1 | 3, 5-DISUBSTITUTED AND 3,5,7-TRISUBSTITUTED-3H-OXAZOLO [4,5-d]PYRIMIDIN-2-ONE COMPOUNDS AND PRODRUGS THEREOF | ANADYS PHARMACEUTICALS INC (US) | 2014-09-10 | — | — | EP | disclosed |
| EP-1824482-B1 | 3, 5-DISUBSTITUTED AND 3,5,7-TRISUBSTITUTED-3H-OXAZOLO AND 3H-THIAZOLO [4,5-d]PYRIMIDIN-2-ONE COMPOUNDS AND PRODRUGS THEREOF | ANADYS PHARMACEUTICALS INC (US) | 2014-02-12 | — | — | EP | disclosed |
| US-8475801-B2 | IgE CH3 peptide vaccine | Pfizer Vaccines, LCC (US) | 2013-07-02 | — | — | US | disclosed |
| US-20120294848-A1 | IGE CH3 Peptide Vaccine | PFIZER VACCINES LLC (US) | 2012-11-22 | — | — | US | disclosed |
| EP-1824482-A4 | 3, 5-DISUBSTITUTED AND 3,5,7-TRISUBSTITUTED-3H-OXAZOLO AND 3H-THIAZOLO [4,5-d]PYRIMIDIN-2-ONE COMPOUNDS AND PRODRUGS THEREOF | ANADYS PHARMACEUTICALS INC (US) | 2009-08-26 | — | — | EP | disclosed |
| EP-1824482-A1 | 3, 5-DISUBSTITUTED AND 3,5,7-TRISUBSTITUTED-3H-OXAZOLO AND 3H-THIAZOLO [4,5-d]PYRIMIDIN-2-ONE COMPOUNDS AND PRODRUGS THEREOF | Anadys Pharmaceuticals, Inc. (US) | 2007-08-29 | — | — | EP | disclosed |
| US-20060160830-A1 | Immunomodulators; hepatitis C virus; 5-amino-3-(O-D-ribofuranosylthiazolo[4,5-d]pyrimidine-2,7(3H,6H) dione (7-thia-8-oxoguanosine) | ANADYS PHARMACEUTICALS, INC. (US) | 2006-07-20 | — | — | US | disclosed |
| WO-2006066080-A1 | 3, 5-DISUBSTITUTED AND 3,5,7-TRISUBSTITUTED-3H-OXAZOLO AND 3H-THIAZOLO [4,5-d]PYRIMIDIN-2-ONE COMPOUNDS AND PRODRUGS THEREOF | ANADYS PHARMACEUTICALS, INC. (US) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160830-A1 | Immunomodulators; hepatitis C virus; 5-amino-3-(O-D-ribofuranosylthiazolo[4,5-d]pyrimidine-2,7(3H,6H) dione (7-thia-8-oxoguanosine) | HAVCR2, IFNG, TPMT | PDPK1 3242/4885PARP1 2047/4885ACHE 3332/4885 |
| US-20180000824-A1 | COMBINED TREATMENT WITH A TLR7 AGONIST AND AN HBV CAPSID ASSEMBLY INHIBITOR | TLR7, TLR9, HAVCR2 | PDPK1 2891/4885PARP1 742/4885ACHE 4873/4885 |
| US-20120294848-A1 | IGE CH3 Peptide Vaccine | PTMS, FCGRT, TSLP | PDPK1 4676/4885PARP1 4284/4885ACHE 609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.